TMAO links reduced kidney function to higher atherosclerotic cardiovascular risk.

Trimethylamine N-oxide (TMAO), a gut microbiota-derived metabolite, serves as a critical biomarker and pathological driver linking renal impairment with cardiovascular disease.

Renal clearance and the bidirectional feedback loop

• Impaired clearance: Because renal excretion via glomerular filtration is the dominant pathway for clearing TMAO (accounting for approximately 95% of its systemic elimination), reduced kidney function directly leads to its systemic accumulation.
• Renal injury loop: Beyond passive accumulation, elevated circulating TMAO actively drives a bidirectional pathological feedback loop by promoting renal inflammation, tubulointerstitial fibrosis, and progressive kidney injury, further accelerating GFR decline.

Atherosclerotic cardiovascular risk and mechanisms

• Elevated clinical risk: Large-scale prospective cohort studies demonstrate that higher circulating TMAO is associated with a 10% to 30% increased risk of major adverse cardiovascular events (MACE) per standard deviation increment. This risk rises to 1.5- to 2-fold in secondary prevention and acute coronary settings.
• Proatherogenic pathways: Mechanistically, TMAO promotes vascular inflammation, endothelial dysfunction, and oxidative stress. It upregulates CD36 scavenger receptors to accelerate macrophage foam cell formation and enhances intracellular calcium signaling to drive platelet hyperreactivity and arterial thrombosis.
• Advanced plaque pathology: Rather than initiating early, subclinical calcification (such as coronary artery calcium in healthy, younger adults), TMAO primarily drives advanced plaque vulnerability, thrombosis, and acute clinical events.

Bottom line

• Reduced kidney function directly impairs TMAO clearance, initiating a harmful bidirectional feedback loop of renal damage while simultaneously accelerating advanced atherosclerotic cardiovascular disease and thrombotic risk.